AstraZeneca, which developed the corona virus vaccine in contingition with the University of Oxford, has updated its data and published a new report following criticism from the US Institute of Allergy and Infectious Diseases. The vaccine is 76 percent protective against symptomatic Covid-19 and 100 percent protective against severe disease, the new report said. It was repeated that the vaccine did not cause blood clotting. Three days ago, it was announced that the vaccine was 79 percent effective.
The pharmaceutical company AstraZeneca argued that its vaccine, which has caused controversy due to its side effects, provides 76 percent protection against the new type of coronavirus (Covid-19).
New studies have been carried out on the Covid-19 vaccine developed with the University of Oxford, AstraZeneca said in a statement.
The statement noted that new studies have found that the vaccine provides strong protection, and that the vaccine is 76 percent effective in preventing Covid-19.
On March 22nd, AstraZeneca shared data on interim safety and efficacy analyses of phase 3 of the Covid-19 vaccine, which is ongoing on 32,449 people in the United States.
The U.S. Data and Security Monitoring Board said on March 23rd that it was concerned that AstraZeneca may have provided a lack of insight into the useful data.
To allow the use of the AstraZeneca vaccine in the U.S., the Food and Drug Administration and the Centers for Disease Control and Prevention must approve the vaccine after a comprehensive assessment of the data provided by independent advisory committees.
The administration of Oxford-AstraZeneca, one of the first vaccines developed against Covid-19, was temporarily halted in some countries on suspicion that it could lead to blood clotting, causing conditions such as vascular obstruction and pulmonary embolism.
“It should continue to be used to save lives,” the World Health Organization said, noting that the benefits of the vaccine outstrighed its risks.
The European Union Medicines Agency and the UK Medicines and Healthcare Products Regulatory Agency also recommended the use of the vaccine.